Loading...
Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study.
Kamar, Nassim Abravanel, Florence Behrendt, Patrick Hofmann, Jörg Pageaux, Georges Phillippe Barbet, Christelle Moal, Valérie Couzi, Lionel Horvatits, Thomas De Man, Robert A
Kamar, Nassim
Abravanel, Florence
Behrendt, Patrick
Hofmann, Jörg
Pageaux, Georges Phillippe
Barbet, Christelle
Moal, Valérie
Couzi, Lionel
Horvatits, Thomas
De Man, Robert A
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2020-09-01
Submitted date
2019-03-23
Files
Other Titles
Abstract
Background. Ribavirin is currently recommended for treating chronic hepatitis E virus (HEV) infection. This retrospective European multicenter study aimed to assess the sustained virological response (SVR) in a large cohort of solid organ transplant (SOT) recipients with chronic HEV infection treated with ribavirin monotherapy (N = 255), to identify the predictive factors for SVR, and to evaluate the impact of HEV RNA mutations on virological response. Methods. Data from 255 SOT recipients with chronic HEV infection from 30 European centers were analyzed. Ribavirin was given at the median dose of 600 (range, 29–1200) mg/day (mean, 8.6 ± 3.6 mg/kg/day) for a median duration of 3 (range, 0.25–18) months. Results. After a first course of ribavirin, the SVR rate was 81.2%. It increased to 89.8% when some patients were offered a second course of ribavirin. An increased lymphocyte count at the initiation of therapy was a predictive factor for SVR, while poor hematological tolerance of ribavirin requiring its dose reduction (28%) and blood transfusion (15.7%) were associated with more relapse after ribavirin cessation. Pretreatment HEV polymerase mutations and de novo mutations under ribavirin did not have a negative impact on HEV clearance. Anemia was the main adverse event. Conclusions. This large-scale retrospective study confirms that ribavirin is highly efficient for treating chronic HEV infection in SOT recipients and shows that the predominant HEV RNA polymerase mutations found in this study do not affect the rate of HEV clearance.
Citation
Affiliation
Publisher
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
EISSN
1537-6591
ISBN
ISMN
Gov't Doc #
Sponsors
License
Attribution 4.0 International